Brief: Urogen Pharma Reports Third Quarter Results

UroGen Pharma

10/11/2022 13:11

Nov 10 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * Q3 LOSS PER SHARE $1.13
    * UROGEN PHARMA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
AND
RECENT CORPORATE DEVELOPMENTS
    * Q3 2022 NET PRODUCT REVENUE OF JELMYTO $16.1 MILLION
VERSUS
$11.4 MILLION Q3 OF 2021
    * UROGEN PHARMA - FULL ENROLLMENT OF ENVISION PHASE 3 TRIAL
WITH
UGN-102 IN LG-IR-NMIBC EXPECTED AS SOON AS END OF NOVEMBER 2022
    * Q3 EARNINGS PER SHARE VIEW $-1.16 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBwJ7Q6Ka 
Further company coverage:  UR8.F 
 ((reuters.briefs@thomsonreuters.com;))